PMID: 9525675Apr 3, 1998Paper

Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1

Journal of Virology
David C MontefioriNorman L Letvin

Abstract

The magnitude and breadth of neutralizing antibodies raised in response to infection with chimeric simian-human immunodeficiency virus (SHIV) in rhesus macaques were evaluated. Infection with either SHIV-HXB2, SHIV-89.6, or SHIV-89.6PD raised high-titer neutralizing antibodies to the homologous SHIV (SHIV-89.6P in the case of SHIV-89.6PD-infected animals) and significant titers of neutralizing antibodies to human immunodeficiency virus type 1 (HIV-1) strains MN and SF-2. With few exceptions, however, titers of neutralizing antibodies to heterologous SHIV were low or undetectable. The antibodies occasionally neutralized heterologous primary isolates of HIV-1; these antibodies required >40 weeks of infection to reach detectable levels. Notable was the potent neutralization of the HIV-1 89.6 primary isolate by serum samples from SHIV-89.6-infected macaques. These results demonstrate that SHIV-HXB2, SHIV-89.6, and SHIV-89.6P possess highly divergent, strain-specific neutralization epitopes. The results also provide insights into the requirements for raising neutralizing antibodies to primary isolates of HIV-1.

References

Mar 1, 1992·AIDS Research and Human Retroviruses·R Shibata, A Adachi
Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P L EarlB Moss
Nov 1, 1995·Journal of Virology·J T LiJ G Sodroski
Jul 1, 1995·The Journal of Experimental Medicine·Q J Sattentau, J P Moore
Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·P A LuciwC Cheng-Mayer
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·C C BroderR W Doms
Jun 1, 1994·AIDS Research and Human Retroviruses·T J Matthews
Jun 1, 1994·AIDS Research and Human Retroviruses·C V Hanson
Feb 1, 1996·Journal of Virology·T M RichardsonR W Doms
Dec 1, 1995·Nature Structural Biology·M LuP S Kim

❮ Previous
Next ❯

Citations

Mar 5, 2002·Nature Medicine·Mark B Feinberg, John P Moore
Aug 10, 2020·Current Opinion in HIV and AIDS·Anya M Bauer, Katharine J Bar
Sep 10, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·Y LuC J Miller
Jan 17, 2002·Immunopharmacology and Immunotoxicology·Y LuY H Chen
May 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Luis R MirandaLisa A Cavacini
Nov 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Masashi ShingaiMalcolm A Martin
Feb 4, 1999·Nature Medicine·J P Moore, D R Burton
Jan 15, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jeffrey T SafritUNKNOWN Ghent IAS Working Group on HIV in Women Children
Feb 24, 2005·AIDS Research and Human Retroviruses·Oliver HartleyJohn P Moore
Jun 5, 1999·AIDS Research and Human Retroviruses·D C Montefiori, T G Evans
Nov 13, 1999·Journal of Virology·J M CrawfordD C Montefiori
Jun 19, 2007·Trends in Biotechnology·Zandrea AmbroseTheodora Hatziioannou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.